Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$2.71
+7.1%
$2.28
$1.11
$17.88
$52.82M1.57422,139 shs337,446 shs
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$1.20
+9.1%
$1.17
$7.80
$12.38
$20.70MN/A41,322 shs500,328 shs
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.51
+8.6%
$1.64
$1.35
$53.79
$18.42M-0.07200,326 shs133,331 shs
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
$5.01
-1.2%
$3.39
$1.31
$6.90
$8.22M-0.79139,931 shs20,691 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
+5.86%+8.12%-20.89%+93.14%-83.59%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
0.00%+7.62%-10.32%0.00%-67.71%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
+2.21%-3.47%-26.84%-17.75%-92.68%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
-0.78%+8.10%+67.33%+97.28%-20.47%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
1.6439 of 5 stars
3.51.00.00.00.61.70.6
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.0263 of 5 stars
3.14.00.00.00.01.70.6
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
0.4899 of 5 stars
0.05.00.00.00.60.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
3.00
Buy$18.00564.21% Upside
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
0.00
N/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
2.25
Hold$12.17705.74% Upside
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TCRT, QTTB, ANVS, and JATT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $12.00
5/15/2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$26.00 ➝ $17.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/A$0.67 per shareN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/A$0.04 per share27.08($0.53) per shareN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
$1.16M15.88N/AN/A$0.47 per share3.21
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
$10K821.64N/AN/A$1.29 per share3.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$24.59M-$2.16N/AN/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$6.85MN/A0.00N/AN/A-49.58%2.84%N/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$47.73M-$4.94N/AN/AN/AN/A-447.33%-59.77%8/6/2025 (Estimated)
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
-$4.68M-$2.54N/AN/AN/A-169.34%-124.28%8/13/2025 (Estimated)

Latest TCRT, QTTB, ANVS, and JATT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
-$4.50-$0.67+$3.83-$0.67N/A$0.00 million
5/13/2025Q1 2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.47-$0.32+$0.15-$0.32N/AN/A
5/8/2025Q1 2025
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
-$1.23-$0.90+$0.33-$0.90N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/AN/A
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/A
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
N/AN/AN/AN/AN/A
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/A
10.68
10.68
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/A
0.15
0.15
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
1.68
4.71
4.71
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
N/A
1.00
1.00

Institutional Ownership

CompanyInstitutional Ownership
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.83%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
47.97%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
31.32%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
27.72%

Insider Ownership

CompanyInsider Ownership
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
20.80%
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
20.00%
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
40.00%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
16.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
319.49 million15.43 millionOptionable
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
317.25 million13.80 millionNot Optionable
Q32 Bio Inc. stock logo
QTTB
Q32 Bio
3912.20 million7.32 millionN/A
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
401.64 million1.38 millionNo Data

Recent News About These Companies

Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Annovis Bio stock logo

Annovis Bio NYSE:ANVS

$2.71 +0.18 (+7.11%)
Closing price 03:57 PM Eastern
Extended Trading
$2.72 +0.01 (+0.37%)
As of 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

JATT Acquisition stock logo

JATT Acquisition NYSE:JATT

$1.20 +0.10 (+9.09%)
As of 07/8/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Q32 Bio stock logo

Q32 Bio NASDAQ:QTTB

$1.51 +0.12 (+8.63%)
Closing price 04:00 PM Eastern
Extended Trading
$1.54 +0.03 (+2.32%)
As of 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Alaunos Therapeutics stock logo

Alaunos Therapeutics NASDAQ:TCRT

$5.01 -0.06 (-1.18%)
Closing price 03:59 PM Eastern
Extended Trading
$4.96 -0.05 (-1.10%)
As of 05:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.